drugset / Trial / NCT02589600
Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)
Phase 4
Completed
310 enrolled
Susan L. Greenspan
National Institute on Aging (NIA) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The goal of this study is to perform the first fracture reduction clinical trial with a potent antiresorptive agent (intravenous zoledronic acid) in the most vulnerable long-term care population.
Timeline
- Start
- 2016-01
- Primary completion
- 2022-06-22
- Completion
- 2022-06-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zoledronic acid | Other / unclassified | 5 mg | Intravenous |